BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 12820435)

  • 1. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
    Zeamari S; Floot B; van der Vange N; Stewart FA
    Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
    Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
    BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study.
    Rossi CR; Foletto M; Mocellin S; Pilati P; De SM; Deraco M; Cavaliere F; Palatini P; Guasti F; Scalerta R; Lise M
    Cancer; 2002 Jan; 94(2):492-9. PubMed ID: 11900234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
    Aarts F; Bleichrodt RP; de Man B; Lomme R; Boerman OC; Hendriks T
    Ann Surg Oncol; 2008 Nov; 15(11):3299-307. PubMed ID: 18712445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
    Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
    Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
    Lim SJ; Cormier JN; Feig BW; Mansfield PF; Benjamin RS; Griffin JR; Chase JL; Pisters PW; Pollock RE; Hunt KK
    Ann Surg Oncol; 2007 Aug; 14(8):2309-18. PubMed ID: 17541691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
    Ma GY; Bartlett DL; Reed E; Figg WD; Lush RM; Lee KB; Libutti SK; Alexander HR
    Cancer J Sci Am; 1997; 3(3):174-9. PubMed ID: 9161783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of Chemoperfusion Treatment for Abdominal Carcinomatosis.
    Bespalov VG; Belyaeva OA; Kireeva GS; Senchik KY; Stukov AN; Belyaev AM
    Bull Exp Biol Med; 2015 May; 159(1):81-4. PubMed ID: 26033596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
    Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L
    Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
    van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
    Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
    Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
    Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model.
    Klaver YL; Hendriks T; Lomme RM; Rutten HJ; Bleichrodt RP; de Hingh IH
    Br J Surg; 2010 Dec; 97(12):1874-80. PubMed ID: 20806291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
    Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
    Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].
    Bespalov VG; Kireeva GS; Belyaeva OA; Senchik KY; Stukov AN; Gafton GI; Soloviev LA; Vasilchenko MV; Guseinov KD; Alexeev VV; Belyaev AM
    Vopr Onkol; 2015; 61(4):647-52. PubMed ID: 26571838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children.
    Reingruber B; Boettcher MI; Klein P; Hohenberger W; Pelz JO
    J Pediatr Surg; 2007 Sep; 42(9):E17-21. PubMed ID: 17848227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
    Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
    J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy.
    van Ruth S; Verwaal VJ; Hart AA; van Slooten GW; Zoetmulder FA
    Anticancer Res; 2003; 23(2B):1501-8. PubMed ID: 12820416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
    Scaringi S; Kianmanesh R; Sabate JM; Facchiano E; Jouet P; Coffin B; Parmentier G; Hay JM; Flamant Y; Msika S
    Eur J Surg Oncol; 2008 Nov; 34(11):1246-52. PubMed ID: 18222622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
    Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
    Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.